vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Zhihu Inc. (ZH). Click either name above to swap in a different company.
BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($156.4M vs $92.0M, roughly 1.7× Zhihu Inc.). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs -19.0%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Zhihu is a Chinese social question and answer site and news aggregator. Originally based in Chengdu and with creators from Sichuan, China, the website launched on January 26, 2011. The number of registered users on Zhihu exceeded 10 million by the end of 2013, and reached 17 million as of May 2015, with 250 million monthly page views.
BCRX vs ZH — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $92.0M |
| Net Profit | — | $30.1M |
| Gross Margin | — | 53.6% |
| Operating Margin | 13.6% | — |
| Net Margin | — | 32.7% |
| Revenue YoY | 7.5% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | $92.0M | ||
| Q4 25 | $406.6M | — | ||
| Q3 25 | $159.4M | $92.6M | ||
| Q2 25 | $163.4M | $100.1M | ||
| Q1 25 | $145.5M | $100.6M | ||
| Q4 24 | $131.5M | — | ||
| Q3 24 | $117.1M | $120.4M | ||
| Q2 24 | $109.3M | $128.5M |
| Q1 26 | — | $30.1M | ||
| Q4 25 | $245.8M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $5.1M | — | ||
| Q1 25 | $32.0K | — | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | $-1.3M | ||
| Q2 24 | $-12.7M | $-11.1M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | 61.3% | ||
| Q2 25 | 98.3% | 62.5% | ||
| Q1 25 | 96.9% | 61.8% | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | 63.9% | ||
| Q2 24 | 98.4% | 59.6% |
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | — | ||
| Q3 25 | 18.6% | -15.1% | ||
| Q2 25 | 18.2% | -12.7% | ||
| Q1 25 | 14.6% | — | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | 6.6% | -10.0% | ||
| Q2 24 | 8.0% | -19.7% |
| Q1 26 | — | 32.7% | ||
| Q4 25 | 60.5% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | -1.1% | ||
| Q2 24 | -11.6% | -8.6% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.06 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $481.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $554.1M |
| Total Assets | $465.1M | $742.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | $481.8M | ||
| Q4 25 | $274.7M | — | ||
| Q3 25 | $212.9M | $383.5M | ||
| Q2 25 | $260.0M | $446.5M | ||
| Q1 25 | $295.1M | $446.5M | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | $458.0M | ||
| Q2 24 | $78.4M | $434.7M |
| Q1 26 | — | $554.1M | ||
| Q4 25 | $-119.2M | — | ||
| Q3 25 | $-387.9M | $578.9M | ||
| Q2 25 | $-421.6M | $587.4M | ||
| Q1 25 | $-451.9M | $573.2M | ||
| Q4 24 | $-475.9M | — | ||
| Q3 24 | $-468.6M | $619.2M | ||
| Q2 24 | $-475.6M | $605.5M |
| Q1 26 | $465.1M | $742.3M | ||
| Q4 25 | $514.2M | — | ||
| Q3 25 | $446.4M | $772.8M | ||
| Q2 25 | $457.2M | $802.2M | ||
| Q1 25 | $480.0M | $783.1M | ||
| Q4 24 | $490.4M | — | ||
| Q3 24 | $491.3M | $856.2M | ||
| Q2 24 | $472.4M | $840.5M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
ZH
Segment breakdown not available.
